# NCT07183189 (NCT07183189)

> A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07183189
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Conditions: Non-small Cell Lung Cancer
- Interventions: SHR-A2009 ; Aumolertinib; Aumolertinib
- Enrollment: 582
- Primary outcome: Progression-free survival (PFS) assessed by BICR according to RECIST v1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct07183189